- Home
- QTTB vs WXM Comparison
QTTB vs WXM Comparison
Compare QTTB & WXM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QTTB
- WXM
- Stock Information
- Founded
- QTTB 2015
- WXM 2009
- Country
- QTTB United States
- WXM China
- Employees
- QTTB N/A
- WXM N/A
- Industry
- QTTB Biotechnology: Pharmaceutical Preparations
- WXM
- Sector
- QTTB Health Care
- WXM
- Exchange
- QTTB Nasdaq
- WXM NYSE
- Market Cap
- QTTB 19.0M
- WXM 15.3M
- IPO Year
- QTTB N/A
- WXM 2025
- Fundamental
- Price
- QTTB $1.92
- WXM $2.20
- Analyst Decision
- QTTB Hold
- WXM
- Analyst Count
- QTTB 8
- WXM 0
- Target Price
- QTTB $24.00
- WXM N/A
- AVG Volume (30 Days)
- QTTB 90.3K
- WXM 100.6K
- Earning Date
- QTTB 05-08-2025
- WXM 01-01-0001
- Dividend Yield
- QTTB N/A
- WXM N/A
- EPS Growth
- QTTB N/A
- WXM 67.61
- EPS
- QTTB N/A
- WXM 0.18
- Revenue
- QTTB N/A
- WXM $15,524,259.00
- Revenue This Year
- QTTB N/A
- WXM N/A
- Revenue Next Year
- QTTB N/A
- WXM N/A
- P/E Ratio
- QTTB N/A
- WXM $14.47
- Revenue Growth
- QTTB N/A
- WXM 10.86
- 52 Week Low
- QTTB $1.38
- WXM $1.52
- 52 Week High
- QTTB $53.79
- WXM $7.99
- Technical
- Relative Strength Index (RSI)
- QTTB 57.55
- WXM N/A
- Support Level
- QTTB $1.56
- WXM N/A
- Resistance Level
- QTTB $1.96
- WXM N/A
- Average True Range (ATR)
- QTTB 0.15
- WXM 0.00
- MACD
- QTTB 0.03
- WXM 0.00
- Stochastic Oscillator
- QTTB 87.80
- WXM 0.00
About QTTB Q32 Bio Inc. Common Stock
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
About WXM WF INTERNATIONAL LIMITED
WF International Ltd is engaged in the provision of supply, installation, fitting-out and maintenance services for HVAC system and floor heating systems. It provides the supply, installation and fitting-out services for HVAC systems for large-scaled commercial projects consisting of offices, hotels, manufactures, airports and hospitals, such as the International Finance Square HVAC projects across China, Chengdu Vanke Charm City, Chengdu Raffles Plaza, Chengdu Yinshi Plaza, Chengdu Metro No. Ten Line, and Panzhihua Jinhai Hotel.